Is Multiple Myeloma a Greater Threat to Black Patients? Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
A Gentler Standard for Acute Promyelocytic Leukemia in Kids ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
Vaccinated Blood Cancer Patients Still at Risk for Severe COVID-19 Those with hematologic malignancies also remain at higher risk of mortality as well Nov 08, 2021
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
Longer Hydroxyurea Tied to Improved Sickle-Cell Heart Issues Kids on treatment for less than 1 year had a significantly greater prevalence of LV dilation Sep 16, 2021
9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
Life Expectancy Still Lower for Blood or Marrow Transplant Recipients Although late mortality has decreased over the past 40 years Sep 09, 2021
Liver Toxicity in Gene Therapy Trials Could Merit Stricter Entry Criteria FDA panel weighs in on lower vector doses and role of animal studies Sep 03, 2021
Adding Mycophenolate Mofetil Improves Outcomes in ITP "Somewhat decreased" quality of life, however, British study finds Sep 01, 2021
Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphoma Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
Are Hemoglobin Cutoffs for Anemia Outdated? A growing call for WHO criteria to be tightened Aug 06, 2021
Woman Develops Tiny Blood Spots on Her Body After COVID Shot Case highlights need for quick diagnosis and management of rare disorder Aug 05, 2021
Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
Add-On Venetoclax Promising in Younger, Fit AML Patients "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
Call in the T-Cell Cavalry to Fight COVID in the Immunocompromised Preliminary research suggests immunotherapy could play role in protecting vaccine non-responders Jul 29, 2021
Shingrix OK'd for Immunocompromised Adults CDC's vaccine committee currently discussing vaccine for this population, manufacturer says Jul 26, 2021
Keytruda Before, After Surgery Improves Outcome in TNBC Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021
Raise a Glass? Study Tallies Cancer Cases From Booze Heavy drinking habits accounted for about half of new alcohol-associated cases Jul 13, 2021
Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer? Use of chemo reduced radiation-induced cancers, and may prolong OS in low-PSA subgroup Jul 07, 2021
Infusion Centers or EDs for Sickle Cell Crises? Adults with SCD treated in infusion centers had improved outcomes in three key measures Jul 06, 2021
IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA ODAC recommends deferring approval of new PD-1 inhibitor until confirmatory trial results are in Jun 24, 2021
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Another CAR-T Impresses in Follicular Lymphoma Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
With Supplements, ADT in Prostate Cancer of Little Threat to Bone Density Study suggests calcium/vitamin D alone sufficient for long-duration therapy Jun 03, 2021
Family Alleges Profit Motives Played Role in 3-Year-Old's Death Parents charge care delays for child with hydrocephalus were tied to arrangements for star doctor May 25, 2021
Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma Commonly used regimens with autologous transplant improved survival May 06, 2021
Vadadustat Matches Standard for CKD-Related Anemia, With Caveat Jury still out on drug's heart safety, which differed depending on dialysis dependence Apr 28, 2021
Healthy Lifestyle May Mitigate Heart Risks for Young Cancer Survivors Literature reviews find particularly persistent cardiovascular complications in these patients Apr 28, 2021
Why Clotting Happens When Platelets Are Low A hematologist explains the counterintuitive concept of clots with low platelets Apr 23, 2021
Poloxamer 188 Flops for Sickle Cell Disease Pain Study found no difference in duration of vaso-occlusive episodes versus placebo Apr 20, 2021
Targeted Drug Yields Durable Responses in Rare Blood Neoplasm Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor Apr 13, 2021
